



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/035,831	12/28/2001	William P. Van Antwerp	047711-0273	1788

7590 04/10/2007
Irvin C. Harrington, III
FOLEY & LARDNER
35th Floor
2029 Century Park East
Los Angeles, CA 90067-3021

EXAMINER

BOUCHELLE, LAURA A

ART UNIT	PAPER NUMBER
----------	--------------

3763

SHORTENED STATUTORY PERIOD OF RESPONSE	MAIL DATE	DELIVERY MODE
3 MONTHS	04/10/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

If NO period for reply is specified above, the maximum statutory period will apply and will expire 6 MONTHS from the mailing date of this communication.

Office Action Summary

Application No.

10/035,831

Applicant(s)

VAN ANTWERP ET AL.

Examiner

Laura A. Bouchelle

Art Unit

3763

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 26 December 2006.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-7,9-27,68 and 87-101 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☒ Claim(s) 1-7,9-27,68 and 87-101 is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☐ Claim(s) _____ are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. _____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date 1/14/04.
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. _____.
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: _____.

DETAILED ACTION

Claim Rejections - 35 USC § 102

1. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless –

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

2. Claims 1, 7, 9-25, 68, 87-89, 91-95, 97-101 are rejected under 35 U.S.C. 102(b) as being anticipated by Nelson (US 5702372). Nelson discloses a lined infusion catheter comprising a layer that reduces diffusion of small particles through the tube, wherein the layer is formed of PTFE or polyurethane (Col. 4, lines 8-15). The catheter comprises an outer layer formed of silicone (Col. 1, lines 5-10). Nelson teaches a lined infusion catheter comprising a liner made of Teflon that is relatively nonporous to prevent contaminants such as carbon dioxide from diffusing into the lumen and denaturing the insulin (Col. 4, lines 9-15). Adjusting the porosity and thickness of the liner is inherently capable of reducing the diffusion of contaminants any amount.

Claim Rejections - 35 USC § 103

3. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person

Art Unit: 3763

having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

4. Claims 2 and 69 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nelson in view of Ash et al (US 6042561). Claims 2 and 69 differ from Nelson in calling for the insulin formulation to be maintained in the tubing. Ash teaches an infusion device comprising a continuous insulin infusion pump wherein the insulin is maintained in the tubing since the delivery is continuous (Col. 1, line 63 – Col. 2, line 10). Therefore, it would have been obvious to one of ordinary skill in the art at the time of invention to modify the device of Nelson to maintain the insulin formulation in the tube as taught by Ash to prevent occlusions or deposits from forming in the tubing.

5. Claim 3 is rejected under 35 U.S.C. 103(a) as being unpatentable over Nelson in view of Brange et al (US 4472385). Claim 3 differs from Nelson in calling for the insulin formulation to be stabilized by being substantially free of deposits or occlusions comprising insulin and an excipient. Brange teaches a stabilized insulin preparation comprising highly purified insulin and an excipient to provide the maximum concentration and stability (Col. 3, lines 45-55). Therefore, it would have been obvious to one of ordinary skill in the art at the time of invention to include in the device of Nelson the insulin formulation of Brange so that the insulin has maximum stability.

6. Claims 4-5 rejected under 35 U.S.C. 103(a) as being unpatentable over Nelson in view of Ash, in further view of Brange. Claim 4 differs from the teachings above in calling for the

Art Unit: 3763

insulin to be a high concentration formulation. Claim 5 calls for the formulation to be greater than about 100 U/ml. Brange teaches a stabilized insulin preparation comprising a high concentration formulation of insulin at a concentration of 40 to 1000 U/ml (Col. 3, lines 50-52). Therefore, it would have been obvious to one of ordinary skill in the art at the time of invention to modify the insulin formulation of Nelson to be of a concentration greater than about 100 U/ml as taught by Brange to achieve the optimal concentration.

7. Claims 26 and 27 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nelson in view of Ekwuribe et al (US 6309633). Claims 26 and 27 differ from Nelson in calling for the protein to be the insulin analogue Lispro. Ekwuribe teaches the use of the insulin analogue Lispro in the place of insulin because Lispro has a more precise action profile than human insulin (Col. 14, lines 7-10). Therefore, it would have been obvious to one of ordinary skill in the art at the time of invention to modify the device of Nelson to have Lispro as taught by Ekwuribe because Lispro has a more precise action profile than human insulin.

8. Claims 90, 96 are rejected under 35 U.S.C. 103(a) as being unpatentable over Nelson in view of Van Antwerp et al (US 6443942). Claims 90, 96 differ from the teachings above in calling for the protein compatible material to contain a PEG moiety. Van Antwerp teaches a medication device with protein stabilizing surface coating wherein the coating includes a PEG moiety that promotes the maintenance of the specific protein's native state (Col. 6, lines 55-65). Therefore, it would have been obvious to one of ordinary skill in the art at the time of invention

Art Unit: 3763

to modify the device of Nelson to include a layer containing PEG moiety as taught by Van Antwerp to promotes the maintenance of the specific protein's native state.

Response to Arguments

9. Applicant's arguments, see pages 9-13, filed 12/26/06, with respect to the rejection(s) of claim(s) Walker in view of Bobo have been fully considered and are persuasive. Therefore, the rejection has been withdrawn. However, upon further consideration, a new ground(s) of rejection is made in view of Nelson as above.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Laura A. Bouchelle whose telephone number is 571-272-2125. The examiner can normally be reached on Monday-Friday 8-4.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Nicholas Lucchesi can be reached on 517-272-4977. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Art Unit: 3763

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Laura A Bouchelle
Examiner
Art Unit 3763



ENCLOSURE

10/035,831